Chugai: Roche initiates clinical trial of Actemra for patients with COVID-19 severe pneumonia

By Statistics

Chugai: Roche initiates clinical trial of Actemra for patients with COVID-19 severe pneumonia

March 19, 2020

Chugai:

Today, we are pleased to announce that Roche has released a press release on clinical trials for coronavirus infection.

“Actemra®”: [Generic name: tocilizumab (genetical recombination)]

Originally, a humanized anti-human IL-6 receptor monoclonal antibody created by Chugai.

This time, COVID-19 will be studied as a treatment for patients with severe pneumonia.

Press Release Details:

Please refer to the following URL.

News Release | Chugai Pharmaceutical

https://www.chugai-pharm.co.jp/news/detail/20200319154500_958.html

Roche – Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

Actemra/RoActemra

is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd

and has been approved in Japan since April 2005.

Actemra/RoActemra is approved in more than 110 countries worldwide.

https://www.roche.com/media/releases/med-cor-2020-03-19.htm

More from tokioX :

  1. COVID-19: Africans oppose discrimination against China: Guangdong Guangzhou / Little Africa
  2. COVID-19: Racist Attack on WHO Tedros: Chinese Pretend to Be Taiwanese
  3. COVID-19: Kaneka supplies PCR reagents: Kaneka Eurogentec / First 200,000 bottles
  4. COVID-19: UK Public Health Service Requests Refund: Test Kit Made in China / Unreliable
  5. COVID-19: FUJIFILM, ‘Avigan®’: Start of Phase III clinical trial in Japan
  6. COVID-19：Osaka Univ Release of protein structure information of new corona:Protein Data Bank (PDBj)
  7. COVID-19: Kurabo Industries, high-precision judgment in 15 minutes of inspection kit: 25,000 yen for specialized institutions